• Redpin bags A round to advance Chantix-controlled gene therapies

    11 days ago - By Fierce Biotech

    Redpin Therapeutics has raised $15.5 million to bankroll chemogenetic R&D. The initial close of the series A positions Redpin to move a controllable gene therapy for the treatment of indications such as epilepsy and pain toward an IND.
    Read more ...